Nasdaq:ABSI
Absci Corp
A pre-commercial biotech firm specializing in off-the-shelf allogeneic cell therapies for immune diseases, currently burning cash to advance its pipeline.
Key Metrics
Investment Thesis
Bull Case
Investors might buy this stock if they believe in the transformative potential of the company's proprietary stem cell platform to cure rare immune disorders. The substantial cash on hand relative to current liabilities suggests there is runway available to fund multiple years of clinical development before needing immediate dilution. Success in a single late-stage trial could validate the technology and unlock significant value from dormant assets.
Bear Case
The company is burning through cash at an alarming rate with no clear path to profitability given the lack of commercial revenue and massive operating expenses. A negative net income trend over the last three years combined with a deficit exceeding half a billion dollars indicates a high probability of insolvency without major capital raises. The stock carries extreme binary risk where the company could go bankrupt if it fails to secure new funding or achieve clinical milestones.
About Absci Corp
Absci Corp (ABSI) is a biotechnology company focused on developing cell-based therapies for immune disorders, primarily targeting the rare disease market. The company leverages proprietary stem cell technologies to generate off-the-shelf allogeneic cellular medicines. Its operations are centered on research and development with minimal current commercial revenue streams.
Analysis
Management Discussion
Management has spent heavily on research and development, with R&D expenses reaching $63.9M while generating only $4.5M in revenue, resulting in a net loss of over $100M. Despite significant capital expenditures and investments in marketable securities, the company continues to accumulate a large deficit, highlighting the early-stage nature of its business model. The cash balance has decreased from $89.7M to $58.2M, signaling a need for further financing to sustain operations.
Industry Overview
The biotechnology sector, particularly in cell and gene therapy, is characterized by long development cycles, high failure rates, and immense capital requirements before commercialization. Companies in this space often trade on future potential rather than current earnings, making valuation metrics like P/E ratios irrelevant for pre-revenue firms. Regulatory hurdles from agencies like the FDA are stringent, requiring extensive clinical data to prove safety and efficacy for novel therapies.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $5.7M | $5.7M | $4.5M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $5.7M | $5.7M | $4.5M |
| Operating Expenses | $112.5M | $121.2M | $113.4M |
| Operating Income | $-106.8M | $-115.5M | $-108.9M |
| R&D | $58.9M | $48.1M | $63.9M |
| G&A | $40.6M | $37.8M | $36.2M |
| Stock-Based Comp | $12.5M | $11.4M | $19.5M |
| D&A | $13.0M | $14.0M | $13.4M |
| Depreciation | $9.7M | $10.6M | $10.0M |
| Amortization | $3.4M | $3.4M | $3.4M |
| Other OpEx | $13.0M | $35.3M | $13.4M |
| Non-Operating Income | $1.4M | $5.0M | $5.9M |
| Interest Expense | $972.0K | $1.0M | — |
| Pre-Tax Income | $-105.4M | $-110.5M | $-103.0M |
| Income Tax | $-461.0K | $100.0K | $70.0K |
| Continuing Ops | $-104.9M | $-110.6M | $-103.1M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-104.9M | $-110.6M | $-103.1M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-104.9M | $-110.6M | $-103.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $186.9M | $120.6M | $133.8M |
| Cash & Equivalents | $60.0M | $72.4M | $41.2M |
| Accounts Receivable | — | — | $0 |
| Prepaid Expenses | $5.9M | $4.5M | $5.5M |
| Other Current Assets | $121.0M | $43.7M | $87.2M |
| Long-Term Assets | $134.1M | $96.7M | $79.8M |
| Intangibles | $51.6M | $48.3M | $44.9M |
| Goodwill | $21.3M | $0 | — |
| Operating Leases | $5.3M | $4.5M | $4.0M |
| Other LT Assets | $55.9M | $44.0M | $30.9M |
| Total Assets | $321.0M | $217.3M | $213.6M |
| Current Liabilities | $30.3M | $29.6M | $28.7M |
| Accounts Payable | $2.4M | $1.5M | $3.5M |
| Current Leases | $1.7M | $1.7M | $1.6M |
| Deferred Revenue | $445.0K | $3.2M | $1.1M |
| Other Current Liab | $5.2M | $3.9M | $15.6M |
| Long-Term Liabilities | $16.3M | $11.6M | $5.8M |
| LT Operating Leases | $7.3M | $5.6M | $4.4M |
| Other LT Liab | $9.0M | $5.0M | $1.4M |
| Total Liabilities | $46.6M | $41.1M | $34.5M |
| Shareholders' Equity | $274.4M | $176.2M | $179.1M |
| Retained Earnings | $-295.9M | $-406.5M | $-509.6M |
| AOCI | $-120.0K | $-37.0K | $-4.0K |
| Total L&E | $321.0M | $217.3M | $213.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-104.9M | $-110.6M | $-103.1M |
| Non-Cash Adjustments | $29.0M | $44.9M | $33.7M |
| Working Capital Changes | $-5.4M | $1.0M | $-3.0M |
| Cash from Operations | $-81.3M | $-64.6M | $-72.4M |
| Capital Expenditures | $16.2M | $860.0K | $404.0K |
| Cash from Investing | $-127.0M | $81.9M | $-41.6M |
| Debt Repayments | $4.7M | $3.0M | $3.4M |
| Cash from Financing | $5.2M | $-4.5M | $82.5M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-203.1M | $12.8M | $-31.5M |
| Beginning Cash | $279.9M | $76.8M | $89.7M |
| Ending Cash | $76.8M | $89.7M | $58.2M |
Frequently Asked Questions
How does Absci Corp make money?
The company's financials indicate a single primary segment driven by research and development activities funded by financing inflows. Revenue is generated from potential future product sales or licensing deals rather than established commercial operations, resulting in negligible current operating revenue compared to massive R&D expenditures. Cash flow is heavily dependent on equity financing to sustain long-term asset growth and operational burn.
What are the main risks for ABSI?
Significant operating losses and a substantial retained earnings deficit indicate an unsustainable cash burn rate relative to current financing capabilities. Complete reliance on external capital markets for funding, as evidenced by heavy cash flow from financing activities, creates vulnerability to market conditions. Lack of commercial revenue streams exposes the company to high failure risk if clinical trials do not succeed or regulatory approval is delayed.
What is ABSI's competitive advantage?
First-mover advantage in developing scalable, off-the-shelf allogeneic cell therapies that avoid the complexities of autologous patient-specific treatments. Proprietary manufacturing processes that aim to reduce production costs and time-to-market for complex cellular medicines. Strategic positioning in high-value rare disease markets with potentially large unmet medical needs.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.